Anti-interleukin 33 treatment alleviates psoriatic dermatitis in mice induced imiquimod
International Immunopharmacology · 2023-08 · 121 · 110480
DOI: 10.1016/j.intimp.2023.110480 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023-08. Verfasst von Dandan Fu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453000, Henan, China. Hauptthemen laut MEDLINE: Psoriasis, Dermatitis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Henan Provincial Science and Technology Research Project, Xinxiang Medical University.
Abstract (Originalsprache)
Interleukin-33(IL-33), is constitutively expressed in the epithelial cells of the skin. It has been reported that IL-33 contributed to the severity of the disease in psoriasis-like mouse models. In the current study, we evaluated the effect of anti-IL-33 antibody (Ab) in imiquimod-induced psoriatic dermatitis in mice. Our observations showed that anti-IL-33 Ab ameliorated the erythema, scaling, epidermal thickness and spleen index. Additionally, we found anti-IL-33 Ab significantly decreased the expression of psoriasis-related cytokines. Moreover, anti-IL-33 Ab significantly reduced Ki-67 positive cells, CD3+CD4+T cells, and CD3+CD8+T cells in the skin lesions. Furthermore, anti-IL-33 Ab treatment down-regulated the expression of phosphorylation of STAT3 and IL-33 in model mouse. These results indicated that the anti-IL-33 Ab alleviated the seriousness of skin lesions, inhibited the activation of the STAT3, lymphocyte infiltration and the secretion of pro-inflammatory cytokines in imiquimod-induced psoriatic dermatitis in mice, suggesting IL-33 may be a therapeutic target for the treatment of psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453000, Henan, China.
- Xinxiang Key Laboratory of Pathogenic Biology, Department of Pathogenic Biology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang 453003, Henan, China.
- Department of Immunology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang 453000, Henan, China; Xinxiang Key Laboratory of Tumor Vaccine and Immunotherapy, Xinxiang Medical University, Xinxiang,…
- Department of Dermatology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453000, Henan, China. Electronic address: zhonwt@xxmu.edu.cn.
Förderung
- Henan Provincial Science and Technology Research Project
- Xinxiang Medical University
Zitieren
APA
Fu, D., Zheng, S., Li, J., Hu, H., Wang, Q., Fu, X., Li, M., Yan, D., Yang, Z., Tian, Z., & Song, X. (2023). Anti-interleukin 33 treatment alleviates psoriatic dermatitis in mice induced imiquimod. International Immunopharmacology, 121, 110480. https://doi.org/10.1016/j.intimp.2023.110480
Vancouver
Fu D, Zheng S, Li J, Hu H, Wang Q, Fu X, et al. Anti-interleukin 33 treatment alleviates psoriatic dermatitis in mice induced imiquimod. International Immunopharmacology. 2023;121:110480. doi:10.1016/j.intimp.2023.110480
BibTeX
@article{Fu2023,
author = {Fu, Dandan and Zheng, Shuting and Li, Jialin and Hu, Hua and Wang, Qingqing and Fu, Xiuyu and Li, Min and Yan, Dong and Yang, Zishan and Tian, Zhongwei and Song, Xiangfeng},
title = {Anti-interleukin 33 treatment alleviates psoriatic dermatitis in mice induced imiquimod},
journal = {International Immunopharmacology},
year = {2023},
volume = {121},
pages = {110480},
doi = {10.1016/j.intimp.2023.110480}
}
EUVIMED